Research Papers:

Dual-targeting nanoparticles with excellent gene transfection efficiency for gene therapy of peritoneal metastasis of colorectal cancer

Ling Li, Rui Deng, Yi Su and Cheng Yang _

PDF  |  HTML  |  How to cite

Oncotarget. 2017; 8:89837-89847. https://doi.org/10.18632/oncotarget.21159

Metrics: PDF 1613 views  |   HTML 2630 views  |   ?  


Ling Li1,*, Rui Deng2,*, Yi Su2 and Cheng Yang1

1The Key Laboratory of Food Colloids and Biotechnology, Ministry of Education, School of Chemical and Material Engineering, Jiangnan University, Wuxi 214122, China

2Hematology Department and Hematopoietic Stem Cell Transplantation Center, Cheng Du Military General Hospital of PLA, Chengdu 610083, China

*These authors contributed equally to this work

Correspondence to:

Cheng Yang, email: [email protected]

Keywords: gene therapy, peritoneal metastasis, colorectal cancer, dual-targeting nanoparticle

Received: May 25, 2017     Accepted: August 26, 2017     Published: September 22, 2017


Colorectal cancer has been one of the most common cancers in the worldwide. Poor patient compliance and serious side effects often associated with conventional therapy (e.g. surgery, radiation, and chemotherapy). Gene therapy may be an alternative strategy. Herein, we developed a dual-targeting nanoparticle with excellent gene transfection efficiency for gene therapy of peritoneal metastasis of colorectal cancer. This nanoparticle can facilitate efficient cellular uptake and promote penetration into nucleus. Meanwhile, this nanoparticle mediated efficient gene transfection in medium with or without serum, which significantly surpassed that of commercial transfection reagents, Lipofectamine 2000 and Lipofectamine 3000. After systemic administration, this nanoparticle loaded with hTRAIL plasmid significantly inhibited peritoneal metastasis of colorectal cancer in vivo. In conclusion, this dual-targeting nanoparticle has great potential to be a gene delivery vector for colorectal cancer therapy.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 21159